Medy-Tox
Key metrics
Earnings
| Revenue, Q3 2026 | ₩59.3bn |
|---|---|
| Revenue QoQ | -13.7% |
| Revenue YoY | -2.8% |
| Operating income, Q3 2026 | ₩15.5bn |
| Operating income QoQ | +226.0% |
| Operating income YoY | +74.5% |
Share buybacks
| Buyback decided, last 3 months | ₩0 |
|---|---|
| Buyback decided, last 3 months, % of shares | Not available |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | Not available |
| Treasury shares cancelled, last 3 months | ₩76.7bn |
| Treasury shares cancelled (number), last 3 months | Not available |
| Treasury shares cancelled, last 3 months, % of shares | Not available |
| Buyback decided, last 12 months | ₩13.0bn |
| Buyback decided, last 12 months, % of shares | Not available |
| Shares acquired, last 12 months | ₩13.0bn |
| Shares acquired, last 12 months, % of shares | Not available |
| Treasury shares cancelled, last 12 months | ₩153.4bn |
| Treasury shares cancelled (number), last 12 months | Not available |
| Treasury shares cancelled, last 12 months, % of shares | Not available |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩0 |
|---|---|
| Rights offering new shares, last 12 months | 0 shares |
| Potential new shares, last 12 months | 0 shares |
| Potential new shares, % of shares | Not available |
| Conversion price adjustments, last 12 months | 0 |
Supply contracts
| Supply contracts, last 12 months | ₩0 |
|---|---|
| Supply contracts vs prior-year revenue | 0.0% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 6 |
|---|---|
| DART filings, previous 3 months | 11 |
Insider transactions
| Open-market buys, last 12 months (shares) | 7,489 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩550m |
| Open-market sells, last 12 months (shares) | 0 shares |
| Open-market sells, last 12 months (amount) | ₩0 |
| Net open-market buying, last 12 months (shares) | 7,489 shares |
| Insiders who bought, last 12 months | 2 |
Insider transactions (last 12 months)
Open-market buys: 7,489 shares (₩550m). Open-market sells: 0 shares (₩0). Net open-market buying: +7,489 shares. Insiders who bought: 2.
| Trade date | Insider (role) | Type | Shares | Price | Amount | |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Gim Min Ju (Non-registered officer) | Other (New appointment) | +220 shares | — | — | |
| Aug 3, 2026 | Jeong Hyeon Ho (Registered director, Controlling shareholder) | Open-market buy | +3,465 shares | ₩70,758 | ₩245m | |
| Jul 30, 2026 | Jeong Hyeon Ho (Registered director, Controlling shareholder) | Open-market buy | +450 shares | ₩71,100 | ₩32m | |
| Jul 29, 2026 | Jeong Hyeon Ho (Registered director, Controlling shareholder) | Open-market buy | +1,000 shares | ₩73,690 | ₩74m | |
| Jul 7, 2026 | Jeong Hyeon Ho (Registered director, Controlling shareholder) | Open-market buy | +1,254 shares | ₩79,012 | ₩99m | |
| Jun 26, 2026 | Jeong Hyeon Ho (Registered director, Controlling shareholder) | Open-market buy | +65 shares | ₩77,000 | ₩5m | |
| Jun 25, 2026 | Jeong Hyeon Ho (Registered director, Controlling shareholder) | Open-market buy | +1,250 shares | ₩75,924 | ₩95m | |
| Mar 27, 2026 | Cheon Yeong Ik (Registered director) | Other (New appointment) | +7,342 shares | — | — | |
| Mar 18, 2026 | Jeong Jin Hyang (Non-registered officer) | Open-market buy | +5 shares | ₩117,300 | ₩586,500 | Reported late |
| Mar 3, 2026 | Jeong Jin Hyang (Non-registered officer) | Other (New appointment) | +35 shares | — | — | Reported late |
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩247.3bn | ₩17.0bn |
| 2024 | ₩228.6bn | ₩20.3bn |
| 2023 | ₩221.1bn | ₩17.3bn |
Filing timeline
-
Medy-Tox quarterly cash dividend of ₩1,200 per share
Medy-Tox will pay a quarterly cash dividend of ₩1,200 per common share, with a dividend yield of 1.8% as reported. The total dividend is ₩7.7bn, with a record date of Oct 29, 2026 and an expected payment date of Nov 13, 2026.